SAN DIEGO As potential cancer therapies proliferate, researchers and clinicians are striving to measure their effectiveness and to more accurately predict which patients will receive the most benefit. At the American Association for Cancer Research 2008 Annual Meeting, April 12-16, 2008, researchers present data on a new role for MRI in brain cancer, how doctors can more effectively measure response to commonly used cancer drugs, and a unique method for predicting the risk of breast cancer spread.
A phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas: Abstract LB306
Results of a phase II trial suggest that lapatinib, currently approved for breast cancer treatment, shows promise for stabilizing disease in patients with liver cancer.
Lapatinib is well-tolerated and may have some activity in hepatocellular carcinoma (HCC), said Joseph Markowitz, M.D., Ph.D., a researcher at The Ohio State University, who works with Tanios Bekaii-Saab, MD, the principal investigator on the study. More work is needed to understand the underlying molecular mechanisms of this cancer.
HCC rates are rising in the United States, which correlates with the increase in hepatitis C-related liver disease, a known risk factor for HCC, Markowitz says. There is also a link to an increased incidence of what we call fatty liver as a result of the increasing rates of obesity and diabetes mellitus in the U.S. population.
Lapatinib blocks the activity of the tyrosine kinase of both epidermal growth factor (EGFR) and HER2/neu, Markowitz says. A dual inhibitor such as lapatinib should be effective in patients who express one or both receptors. Given the lack of curative or even modestly effective treatment options for patients with advanced hepatocellular carcinomas, new therapies are desperately needed, he said.
Markowitz, Bekaii-Saab and colleagues assessed the efficacy of
|Contact: Staci Vernick Goldberg|
American Association for Cancer Research